Literature DB >> 12809987

Genetic analysis of a functional GRIN2A promoter (GT)n repeat in bipolar disorder pedigrees in humans.

Masanari Itokawa1, Kazuo Yamada, Yoshimi Iwayama-Shigeno, Yuichi Ishitsuka, Sevilla Detera-Wadleigh, Takeo Yoshikawa.   

Abstract

Hypofunction of glutamatergic neurotransmission has been hypothesized to underlie the pathophysiology of bipolar affective disorder, as well as schizophrenia. We examined the role of the N-methyl-D-aspartate receptor 2A subunit (GRIN2A) gene on 16p13.3, a region thought to be linked to bipolar disorder, (1) because in a prior study we identified a functional and polymorphic (GT)n repeat in the 5' regulatory region of the gene, with longer alleles showing lower transcriptional activity and an over representation in schizophrenia, and (2) because of the suggestion of a genetic overlap between affective disorder and schizophrenia. Family-based association tests detected a nominally significant preferential transmission of longer alleles in a panel of 96 multiplex bipolar pedigrees. These results support the hypothesis that a hypoglutamatergic state is involved in the pathogenesis of bipolar affective disorder.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12809987     DOI: 10.1016/s0304-3940(03)00501-9

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  16 in total

1.  Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.

Authors:  Carlos A Zarate; Nancy E Brutsche; Lobna Ibrahim; Jose Franco-Chaves; Nancy Diazgranados; Anibal Cravchik; Jessica Selter; Craig A Marquardt; Victoria Liberty; David A Luckenbaugh
Journal:  Biol Psychiatry       Date:  2012-01-31       Impact factor: 13.382

Review 2.  Mood-stabilizers target the brain arachidonic acid cascade.

Authors:  Jagadeesh S Rao; Stanley I Rapoport
Journal:  Curr Mol Pharmacol       Date:  2009-06       Impact factor: 3.339

Review 3.  Novel glutamatergic agents for major depressive disorder and bipolar disorder.

Authors:  Rodrigo Machado-Vieira; Lobna Ibrahim; Ioline D Henter; Carlos A Zarate
Journal:  Pharmacol Biochem Behav       Date:  2011-09-25       Impact factor: 3.533

Review 4.  Glutamatergic modulators: the future of treating mood disorders?

Authors:  Carlos Zarate; Rodrigo Machado-Vieira; Ioline Henter; Lobna Ibrahim; Nancy Diazgranados; Giacomo Salvadore
Journal:  Harv Rev Psychiatry       Date:  2010 Sep-Oct       Impact factor: 3.732

5.  Increased excitotoxicity and neuroinflammatory markers in postmortem frontal cortex from bipolar disorder patients.

Authors:  J S Rao; G J Harry; S I Rapoport; H W Kim
Journal:  Mol Psychiatry       Date:  2009-06-02       Impact factor: 15.992

Review 6.  The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders.

Authors:  Rodrigo Machado-Vieira; Husseini K Manji; Carlos A Zarate
Journal:  Neuroscientist       Date:  2009-05-26       Impact factor: 7.519

7.  Chronic carbamazepine administration reduces N-methyl-D-aspartate receptor-initiated signaling via arachidonic acid in rat brain.

Authors:  Mireille Basselin; Nelly E Villacreses; Mei Chen; Jane M Bell; Stanley I Rapoport
Journal:  Biol Psychiatry       Date:  2007-07-12       Impact factor: 13.382

Review 8.  Expression profiling in neuropsychiatric disorders: emphasis on glutamate receptors in bipolar disorder.

Authors:  Stephen D Ginsberg; Scott E Hemby; John F Smiley
Journal:  Pharmacol Biochem Behav       Date:  2011-10-08       Impact factor: 3.533

9.  Analysis of variations in the glutamate receptor, N-methyl D-aspartate 2A (GRIN2A) gene reveals their relative importance as genetic susceptibility factors for heroin addiction.

Authors:  Bin Zhao; Yongsheng Zhu; Wei Wang; Hai-Min Cui; Yun-Peng Wang; Jiang-Hua Lai
Journal:  PLoS One       Date:  2013-08-05       Impact factor: 3.240

10.  Caffeine interaction with glutamate receptor gene GRIN2A: Parkinson's disease in Swedish population.

Authors:  Naomi Yamada-Fowler; Mats Fredrikson; Peter Söderkvist
Journal:  PLoS One       Date:  2014-06-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.